× We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click our cookies policy for information on how to change your cookie settings.


meta|Evidence - COVID-19

Live meta-analysis and evidence synthesis of therapies for COVID19

tutorial video
En     Fr

Our approach
   

more details ...

Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence of assessment of transitivity assumption plausibility. Calculations by netmeta package.

Interactive explorer of NMA results

2GS-US-540-5774, 10 days, 2020 GS-US-540-5774, 5 days, 20202HC-nCoV (Shanghai), 2020 Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 20201Libster, 20201Khamis, 20202CORIMUNO-19, 2020 EMPACTA, 2020anti-interleukin-6 vs. control 1.06 [0.57; 1.96]1.06 [0.57;1.96]anti-interleukin-6 vs. control 1.06 [0.57; 1.96]anti-interleukin-6 vs. convalescent plasma treatment 2.12 [0.35; 12.82]2.12 [0.35;12.82]anti-interleukin-6 vs. convalescent plasma treatment 2.12 [0.35; 12.82]anti-interleukin-6 vs. hydroxychloroquine 0.74 [0.21; 2.57]0.74 [0.21;2.57]anti-interleukin-6 vs. hydroxychloroquine 0.74 [0.21; 2.57]anti-interleukin-6 vs. interferon 1.27 [0.31; 5.20]1.27 [0.31;5.20]anti-interleukin-6 vs. interferon 1.27 [0.31; 5.20]anti-interleukin-6 vs. remdesivir 1.63 [0.45; 5.92]1.63 [0.45;5.92]anti-interleukin-6 vs. remdesivir 1.63 [0.45; 5.92]control vs. anti-interleukin-6 0.94 [0.51; 1.74]0.94 [0.51;1.74]control vs. anti-interleukin-6 0.94 [0.51; 1.74]control vs. convalescent plasma treatment 2.00 [0.37; 10.85]2.00 [0.37;10.85]control vs. convalescent plasma treatment 2.00 [0.37; 10.85]control vs. hydroxychloroquine 0.70 [0.24; 2.06]0.70 [0.24;2.06]control vs. hydroxychloroquine 0.70 [0.24; 2.06]control vs. interferon 1.20 [0.34; 4.26]1.20 [0.34;4.26]control vs. interferon 1.20 [0.34; 4.26]control vs. remdesivir 1.54 [0.50; 4.78]1.54 [0.50;4.78]control vs. remdesivir 1.54 [0.50; 4.78]convalescent plasma treatment vs. anti-interleukin-6 0.47 [0.08; 2.85]0.47 [0.08;2.85]convalescent plasma treatment vs. anti-interleukin-6 0.47 [0.08; 2.85]convalescent plasma treatment vs. control 0.50 [0.09; 2.71]0.50 [0.09;2.71]convalescent plasma treatment vs. control 0.50 [0.09; 2.71]convalescent plasma treatment vs. hydroxychloroquine 0.35 [0.05; 2.60]0.35 [0.05;2.60]convalescent plasma treatment vs. hydroxychloroquine 0.35 [0.05; 2.60]convalescent plasma treatment vs. interferon 0.60 [0.07; 4.96]0.60 [0.07;4.96]convalescent plasma treatment vs. interferon 0.60 [0.07; 4.96]convalescent plasma treatment vs. remdesivir 0.77 [0.10; 5.89]0.77 [0.10;5.89]convalescent plasma treatment vs. remdesivir 0.77 [0.10; 5.89]hydroxychloroquine vs. anti-interleukin-6 1.35 [0.39; 4.67]1.35 [0.39;4.67]hydroxychloroquine vs. anti-interleukin-6 1.35 [0.39; 4.67]hydroxychloroquine vs. control 1.43 [0.49; 4.21]1.43 [0.49;4.21]hydroxychloroquine vs. control 1.43 [0.49; 4.21]hydroxychloroquine vs. convalescent plasma treatment 2.86 [0.38; 21.26]2.86 [0.38;21.26]hydroxychloroquine vs. convalescent plasma treatment 2.86 [0.38; 21.26]hydroxychloroquine vs. interferon 1.71 [0.32; 9.07]1.71 [0.32;9.07]hydroxychloroquine vs. interferon 1.71 [0.32; 9.07]hydroxychloroquine vs. remdesivir 2.20 [0.46; 10.52]2.20 [0.46;10.52]hydroxychloroquine vs. remdesivir 2.20 [0.46; 10.52]interferon vs. anti-interleukin-6 0.79 [0.19; 3.21]0.79 [0.19;3.21]interferon vs. anti-interleukin-6 0.79 [0.19; 3.21]interferon vs. control 0.83 [0.23; 2.96]0.83 [0.23;2.96]interferon vs. control 0.83 [0.23; 2.96]interferon vs. convalescent plasma treatment 1.67 [0.20; 13.79]1.67 [0.20;13.79]interferon vs. convalescent plasma treatment 1.67 [0.20; 13.79]interferon vs. hydroxychloroquine 0.58 [0.11; 3.08]0.58 [0.11;3.08]interferon vs. hydroxychloroquine 0.58 [0.11; 3.08]interferon vs. remdesivir 1.28 [0.23; 7.02]1.28 [0.23;7.02]interferon vs. remdesivir 1.28 [0.23; 7.02]remdesivir vs. anti-interleukin-6 0.61 [0.17; 2.22]0.61 [0.17;2.22]remdesivir vs. anti-interleukin-6 0.61 [0.17; 2.22]remdesivir vs. control 0.65 [0.21; 2.01]0.65 [0.21;2.01]remdesivir vs. control 0.65 [0.21; 2.01]remdesivir vs. convalescent plasma treatment 1.30 [0.17; 9.93]1.30 [0.17;9.93]remdesivir vs. convalescent plasma treatment 1.30 [0.17; 9.93]remdesivir vs. hydroxychloroquine 0.45 [0.10; 2.17]0.45 [0.10;2.17]remdesivir vs. hydroxychloroquine 0.45 [0.10; 2.17]remdesivir vs. interferon 0.78 [0.14; 4.26]0.78 [0.14;4.26]remdesivir vs. interferon 0.78 [0.14; 4.26]corticosteroidsremdesivirhydroxychloroquineconvalescent plasma treatmentinterferonanti-interleukin-6lopinavir/ritonavircolchicineVitamin Dbaricitinib plus remdesivircontroldirect evidencenetwork meta-analysis

Click on treatment name to display related network evidence

T vs. C corticosteroidsremdesivirhydroxychloroquineconvalescent plasma treatmentinterferonanti-interleukin-6lopinavir/ritonavircolchicineVitamin Dbaricitinib plus remdesivircontrol
corticosteroids---NANANANANANANANANANA
remdesivirNA---0.45
0.10; 2.17
1.30
0.17; 9.93
0.78
0.14; 4.26
0.61
0.17; 2.22
NANANANA0.65
0.21; 2.01
hydroxychloroquineNA2.20
0.46; 10.52
---2.86
0.38; 21.26
1.71
0.32; 9.07
1.35
0.39; 4.67
NANANANA1.43
0.49; 4.21
convalescent plasma treatmentNA0.77
0.10; 5.89
0.35
0.05; 2.60
---0.60
0.07; 4.96
0.47
0.08; 2.85
NANANANA0.50
0.09; 2.71
interferonNA1.28
0.23; 7.02
0.58
0.11; 3.08
1.67
0.20; 13.79
---0.79
0.19; 3.21
NANANANA0.83
0.23; 2.96
anti-interleukin-6NA1.63
0.45; 5.92
0.74
0.21; 2.57
2.12
0.35; 12.82
1.27
0.31; 5.20
---NANANANA1.06
0.57; 1.96
lopinavir/ritonavirNANANANANANA---NANANANA
colchicineNANANANANANANA---NANANA
Vitamin DNANANANANANANANA---NANA
baricitinib plus remdesivirNANANANANANANANANA---NA
controlNA1.54
0.50; 4.78
0.70
0.24; 2.06
2.00
0.37; 10.85
1.20
0.34; 4.26
0.94
0.51; 1.74
NANANANA---

This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

   

- About - Our approach - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons